Q-omics provides the consensus-scored MTCO3P38 profile across patient tissues and cancer cell-line models. MTCO3P38 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MTCO3P38 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MTCO3P38 RNA expression shows 3,966 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRC, and STAD as cancer lineages where MTCO3P38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO3P38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO3P38 survival associations across molecular data types. MTCO3P38 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO3P38 RNA expression–survival associations across cancer types. High MTCO3P38 expression shows unfavorable associations in UCEC, BRCA, ACC, LUAD and UCS, but favorable associations in LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MTCO3P38 RNA expression.
This table summarizes MTCO3P38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO3P38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO3P38 shows lower tumor expression in KIRC and KIRP. The KIRC box plot shows higher MTCO3P38 RNA expression in normal versus tumor tissue (log2 FC = −0.021, t-test p = .003).
This table shows molecular features associated with MTCO3P38 in patient tissues and cancer cell lines. In patient samples, MTCO3P38 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
